Cardiovascular Complication Clinical Trial
— CELARTOfficial title:
Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
Verified date | February 2022 |
Source | Medical University of Gdansk |
Contact | Leszek Tylicki, professor |
Phone | 48583492505 |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.
Status | Recruiting |
Enrollment | 740 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 740 patients, either sex, either non-diabetic or diabetic who underwent the kidney transplantation and who: 1. Are at least three months post-transplantation 2. Have hypertension. 3. Have an estimated glomerular filtration rate greater than or equal to 30 ml/min/1.73 m2 Exclusion Criteria: 1. Pregnant or the possibility of becoming so and breast feeding. 2. Angioedema from an Angiotensin Converting Enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) in the history. 3. Serum potassium greater than 5.5 mmol/l on two or more occasions in the preceding three months. 4. Graft artery stenosis (i.e. psv of more than 200 cm/s in doppler usg) 5. Left ventricular dysfunction that requires an ACE inhibitor or an ARB 6. New immunosuppressive agent was started or previous immunosuppressant stopped in the three months prior to study entry or plan to switch immunosuppressive agents within next three months. 7. Currently on four or more blood pressure pills and have an average blood pressure over three visits greater than 150/100. 8. Currently on an ACE-inhibitor or an ARB or treatment with an ACE inhibitor or ARB after kidney transplantation lasted more than 3 months. 9. Had an acute coronary syndrome, episode of malignant hypertension, stroke or transient ischaemic attack in the three months prior to study entry. |
Country | Name | City | State |
---|---|---|---|
Poland | Medical University | Gdansk |
Lead Sponsor | Collaborator |
---|---|
Medical University of Gdansk | Jagiellonian University, Medical University of Bialystok, Medical University of Silesia, Medical University of Warsaw, Nicolaus Copernicus University, Pomeranian Medical University Szczecin, Poznan Regional Hospital, Wroclaw Medical University |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of composite primary endpoint: | Cardiovascular (CV) death and Resuscitated sudden death and Non-fatal myocardial infarction (MI) and Non-fatal stroke and Unplanned hospitalization for heart failure or unstable angina and Onset of end-stage renal disease (ESRD) and Doubling of baseline serum creatinine concentration, sustained for at least one month. | Up to 5 years | |
Secondary | Occurrence of cardiovascular complications | Cardiovascular (CV) death and Resuscitated sudden death and Non-fatal myocardial infarction (MI) and Non-fatal stroke and Unplanned hospitalization for heart failure or unstable angina | Up to 5 years | |
Secondary | Occurrence of renal complications | ESRD or doubling of baseline serum creatinine | Up to 5 years | |
Secondary | Decline in estimated glomerular filtration rate (eGFR) | Difference in degree of eGFR reduction | Up to 5 years | |
Secondary | Urine albumine concentration | Difference in albuminuria in the measurements available for each patient | after 6 months | |
Secondary | N-acetyl-ß-D-glucosaminidase (NAG) urine excretion | Difference in urine NAF in the measurements available for each patient | after 6 months | |
Secondary | 15-F2t-isoprostanes (isoprostanes) urine excretion | differences in 15-F2t-isoprostanes (isoprostanes) urine excretion in the measurements available for each patient | after 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06089226 -
Parameters Related to Physical Activity Level in SCI
|
||
Recruiting |
NCT04696081 -
Atrial Fibrillation in Active Cancer Patients
|
||
Completed |
NCT05687097 -
Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
|
||
Completed |
NCT03274869 -
Scrub Typhus Infection Induced Cardiovascular Disease
|
||
Completed |
NCT04025086 -
Perioperative Goal Directed Therapy (PGDT) in Spinal Surgery in the Prone Position
|
||
Completed |
NCT03010969 -
Perioperative Endothelial Dysfunction in Patients Undergoing Major Acute Abdominal Surgery
|
||
Completed |
NCT01413815 -
Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients
|
N/A | |
Recruiting |
NCT05077748 -
An 18-year Follow-up Study on OSA in a Population-based Cohort
|
||
Not yet recruiting |
NCT06279000 -
Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery
|
Phase 3 | |
Enrolling by invitation |
NCT06360666 -
Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
|
||
Recruiting |
NCT03977337 -
Perioperative Pulmonary Monitoring in Major Emergency Surgery
|
||
Recruiting |
NCT05996965 -
Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device
|
||
Recruiting |
NCT05349955 -
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
|
N/A | |
Withdrawn |
NCT04435015 -
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05745090 -
N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes Mellitus
|
||
Terminated |
NCT03760159 -
Minimally Invasive Detection of a Sleep Apnoea
|
||
Completed |
NCT04802122 -
Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects.
|
Phase 4 | |
Not yet recruiting |
NCT06419270 -
Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
|
||
Recruiting |
NCT05895669 -
Cardiovascular Outcomes in Orthotopic Liver Transplanted Patients (COLT Study)
|
||
Completed |
NCT05685979 -
Evaluation of Cardiac Functions in Deep Trendelenburg Position
|